EMA

Cloud/SaaS platforms applying machine learning to bioprocess development and manufacturing data to predict outcomes and optimize process parameters — a software analytics layer distinct from the physical PAT hardware (Raman, chromatography, mass spec sensors) generating the data — sold by four specialists (DataHow, Aizon, AlgoCell, Atinary) spanning process-lifecycle modeling, manufacturing-intelligence compliance platforms, and code-free self-driving-lab R&D tools.

Machine-learning software that scans structured and unstructured electronic health records to identify patients meeting a clinical trial's eligibility criteria and to score candidate trial sites on live population data, replacing the manual chart review that has made patient recruitment the biggest bottleneck before a trial can even begin.

AI-driven drug discovery — AlphaFold structure prediction, generative chemistry and physics-based virtual screening — compressing the target-to-candidate pipeline from years to months.

AI-assisted optical coherence tomography and fundus imaging for broad-disease eye screening — diabetic retinopathy, age-related macular degeneration and glaucoma — spanning home-use monitoring devices, multimodal clinic platforms and autonomous AI diagnostic software: Notal Vision and iHealthScreen in the US, Topcon Healthcare (Japan), RetinAI in Switzerland (acquired by EssilorLuxottica), and Airdoc in China.

AI interpretation of digitized whole-slide histology images using self-supervised vision transformers and attention multiple-instance learning to detect tumour foci, grade cancer (Gleason) and predict molecular biomarkers (MSI, PD-L1) from morphology, cutting diagnosis time from days to minutes.

Next-generation antimicrobial compounds and beta-lactamase-inhibitor combinations designed to overcome multi-drug-resistant bacterial infections — a field with real recent approvals but where even a scientifically sound candidate can stall for years on manufacturing paperwork, not efficacy.

A monoclonal antibody chemically linked to a highly potent cytotoxic payload, delivering chemotherapy-grade cell killing selectively to antigen-expressing tumor cells — one of oncology's clearest recent commercial successes, and also a field where a Phase 3 win on efficacy can still surface a real mortality signal.

Integrated sterilising, filling and closing lines that deliver sterile injectables into vials, syringes and cartridges inside ISO 5 / Grade A isolator environments, engineered to meet the revised EU GMP Annex 1 and FDA sterility expectations.

Rigid, fully sealed barrier enclosures that physically separate the sterile processing zone from the operator and surrounding room, using glove ports for manipulation and vaporized hydrogen peroxide for decontamination — the highest-assurance containment format for aseptic fill-finish, sterility testing and cell-therapy manufacturing, increasingly favored over open RABS under the EU's revised Annex 1.

Robotic and software platforms that automate the closed, GMP-grade cell culture and manufacturing steps behind cell and gene therapies — end-to-end automated manufacturing platforms, robotic drug-product handling, and the scheduling/orchestration software coordinating multi-instrument automated workflows — sold by four specialists (Cellares, Multiply Labs, Ori Biotech, HighRes Biosolutions) targeting the labor-intensive, variability-prone manual cell-therapy manufacturing process.

Walk-away microplate processors that automate the full ELISA workflow — sample and reagent dispensing, incubation, washing and photometric reading — for clinical diagnostics, blood-donor screening and biopharma potency/immunogenicity testing, replacing manual multi-step plate handling with a closed, standardized instrument run.

Peristaltic pumps and dosing control loops that deliver nutrients into a bioreactor on a fed-batch or perfusion schedule — the subsystem, usually bundled into a broader bioprocess controller rather than sold standalone, that determines whether a culture starves, overfeeds or hits its intended growth curve.

Benchtop instruments that automate DNA/RNA purification from biological samples — spin-column robots, magnetic-bead purifiers and liquid-biopsy sample-prep platforms — replacing manual extraction kits with standardized, walk-away processing for molecular diagnostics, sequencing library prep and biopharma QC.

Standalone machine-vision systems that inspect every filled vial, ampoule, syringe and cartridge for visible particulates, fill-level deviations, cosmetic glass defects and seal failures at line speed — a dedicated equipment category built around high-resolution cameras, multi-angle lighting and, increasingly, deep-learning defect classification under EU GMP Annex 1 and 21 CFR Part 11.

Naturally occurring or precision-engineered bacterial viruses that selectively lyse a target pathogen without disrupting the rest of the microbiome — a genuine answer to antimicrobial resistance still working through the clinical-trial design problems that have already bankrupted one European pioneer.

Base editors (CBE/ABE) make single-nucleotide changes C·G→T·A and A·T→G·C without double-strand breaks — treating monogenic disease (sickle cell, beta-thalassemia) at up to 90% efficiency with no indels.

The high-shear rotor-stator mixers, multi-shaft dispersers and monobloc cosmetic filling and packaging lines that turn oil and water phases plus recombinant actives into stable, cleanroom-grade emulsions — the manufacturing hardware behind clean-beauty, cell-culture-derived and biotech skincare.

Virtual- and mixed-reality platforms that render human anatomy and surgical procedures as immersive, interactive 3D environments — cloud-based anatomy visualization, haptic surgical simulators and VR procedural-skills training used by hospitals and medical schools in place of cadaver labs and apprenticeship-only training.

Biometric and biomarker-based workplace stress-management programs sold to employers rather than to individual consumers — blood-biomarker test-kit programs, wearable-based multi-stage benchmarking, enterprise API/SDK physiological-data platforms and walk-up kiosk testing — sold by specialty providers (Biostarks, BioStress, Sensor Bio, Komodo Technologies) as a B2B ingredient service for corporate wellness and occupational-health programs.

Physical infrastructure for collecting, processing, cryopreserving and distributing human biospecimens at population or clinical-trial scale — the biospecimen logistics layer, not the genomic-data repository itself: UK Biobank in the EU, BioLife Solutions and Discovery Life Sciences in the US, the China National GeneBank in China, and the newly inaugurated Phenome-India National Biobank (CSIR-IGIB) in India.

Biocompatible surface coatings — mostly UV-curable hydrophilic polymer layers, with drug-eluting and antimicrobial variants — applied to catheters, guidewires, stents and other blood- or tissue-contacting medical devices, supplied by dedicated coating specialists (Surmodics, Biocoat, Hydromer, Harland Medical Systems, Freudenberg Medical) rather than made in-house by device OEMs.

Computation and storage carried out in molecules and living tissue rather than silicon — DNA archives with in-sequencer random access, error-correction codecs tolerating error rates near 14% and sequence loss up to 65%, genetic circuits implementing half and full adders, and biohybrid systems that compute with slime mould and fungal networks.

Bio-based dyes and pigments produced via microbial fermentation and synthetic biology.

Electroceutical devices that treat disease by electrically stimulating nerves rather than with drugs — vagus and splenic nerve neuroimmune modulation, AI-personalized spinal cord stimulation, hypoglossal nerve stimulation and implantable neuromodulation for paralysis and neurological disease: SetPoint Medical, Nevro Corp and Inspire Medical Systems in the US, Galvani Bioelectronics and Onward Medical in Europe, and PINS Medical in China.

Sequencing, single-cell and spatial omics, and biological AI that turn raw reads into decisions — a stack from sample to interpreted multi-omics.

The AI, machine-learning and bioinformatics software-as-a-service layer — cloud platforms, generative biological foundation models and managed analysis pipelines — sold to pharma, biotech and industrial-biology teams rather than run as in-house drug pipelines.

Rapid vaccine-response frameworks that compress outbreak-to-authorization timelines, tabletop and full-scale pandemic exercises that stress-test national response plans, biosecurity policy work closing gaps like unscreened DNA-synthesis orders, and the EU authority reserving manufacturing capacity and stockpiling countermeasures ahead of the next outbreak — the applied governance and readiness layer distinct from the vaccine manufacturing and diagnostics platforms covered elsewhere on this platform.

Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.

Engineered luciferases and fluorescent proteins derived from jellyfish, deep-sea shrimp and other marine organisms, redesigned via directed evolution and computational protein design into ultra-bright, photostable research tools for drug screening, cell imaging and protein-protein interaction detection.

The engineering of medical devices that interface with the body — orthopedic, cardiovascular and neuro implants — sold as capital robotic systems, per-procedure implants and regulated biomaterials under FDA, EU MDR and NMPA oversight.

Bio-inspired surgical adhesives, sealants and hemostatic gels that bond, seal or stop bleeding in wet tissue environments where conventional sutures and staples struggle — drawing on biological adhesion mechanisms such as mussel/oyster adhesive proteins: Tissium in France, Cresilon and Brij Medical in the US, and Adhesys Medical in Germany.

Prosthetic devices that replace a lost limb's function through AI-driven control, touch sensing and direct skeletal attachment — dexterous touch-sensing hands, AI neural prosthetic control, myoelectric pattern recognition and osseointegrated prostheses: Psyonic, Atom Limbs and Coapt in the US, Ottobock and Integrum in Europe, and BrainCo (BrainRobotics) in China.

Advanced planning and scheduling (APS) software that sequences biopharma batch production, supply-chain allocation and project timelines — a distinct software layer from the MES/SCADA systems that execute the recipe on the shop floor — sold by four specialists (Kinaxis, PlanetTogether, Becolve, Aurora Scheduling) spanning supply-chain-level optimization through single-facility batch-recipe and project scheduling.

Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.

In-line sensing, chromatography and mass spectrometry that turn biomanufacturing into data-driven, feedback-controlled production — a stack from probe to real-time release.

Time-series databases that continuously archive every sensor and controller reading from bioreactors and downstream operations, plus the analytics layer on top — multivariate statistics and self-service search — that turns years of accumulated batch data into an early-warning system for process deviations.

Platinum-cured silicone and high-purity thermoplastic elastomer (TPE) tubing engineered for fluid transfer in biopharmaceutical manufacturing — a raw material/component consumable distinct from the fully integrated single-use assemblies it gets built into — sold by four specialist tubing extruders (AdvantaPure, Freudenberg Medical, Saint-Gobain Critical Process Solutions, Raumedic) rather than the systems integrators who assemble tubing into pre-sterilized flow paths.

Contract development and manufacturing organizations providing specialized infrastructure for advanced biopharmaceuticals.

Mass flow controllers and gassing installations that blend oxygen, carbon dioxide, nitrogen and air to precise setpoints and deliver them through a bioreactor's sparger — the subsystem that stabilizes dissolved oxygen and pH and is directly implicated in batch-to-batch yield variability when gas control drifts.

Physical-containment infrastructure — biological safety cabinets, HEPA filtration, autoclave sterilization and BSL-1 to BSL-4 containment — that protects personnel, product and environment in every biotechnology laboratory, governed by NSF/ANSI 49 and EN 12469.

HEPA-filtered containment enclosures that protect the operator, the sample and the environment simultaneously (Class II biosafety cabinets) or the sample alone (laminar flow hoods) — the entry-level, near-universal piece of cleanroom hardware behind every open cell-culture manipulation in biopharma, diagnostics and research labs.

Advanced inline and online bioprocess sensors utilizing optics, capacitance, and spectrometry for real-time monitoring of biomass, metabolites, and dissolved gases in industrial fermentation.

Temperature-controlled, chain-of-custody transport and storage of patient-derived samples between trial sites, central labs, and biorepositories.

Producing CBD, THC and rare cannabinoids (CBG, CBDV, THCV) as platform molecules via engineered yeast fermentation and chemo-enzymatic synthesis, bypassing plant cultivation.

Microbial precision fermentation of hyaluronic acid to a defined molecular weight and pharmacopoeia-grade purity — a B2B biopolymer API for ophthalmic viscoelastics, dermal fillers, orthopedic viscosupplementation and premium cosmetics, under FDA, EMA and NMPA oversight.

Corticosteroid and reproductive-hormone APIs made by mycobacterial fermentation of phytosterol into AD/ADD/9-OHAD precursors, then biocatalytic and semi-synthetic finishing — a globally-offshored manufacturing tier anchored by Olon, Farmabios and Gadea in Europe, Tianjin Tianyao in China, Symbiotec in India and Asymchem's biocatalysis CDMO.

Specialty insurance and brokerage services covering bodily injury and property damage claims arising from biotechnology and pharmaceutical products, structured as layered towers and paired with clinical-trial, E&O and recall coverage.

Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient's own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.

Non-invasive breath analysis using VOC patterns for early diagnosis and continuous disease monitoring.

Computer-aided design software that lets a synthetic biologist draft a genetic construct, simulate its behavior and generate an assembly protocol before a single base pair is synthesized — the digital design layer upstream of both the wet-lab gene-synthesis foundries and the strain-engineering CROs already covered on this site, borrowing the electronic-design-automation model from semiconductor chip design.

Software that tracks the calibration due date of every measurement instrument in a regulated facility, automatically generates work orders, blocks use of out-of-calibration equipment, and keeps the certificate-linked traceability record an auditor will ask for.

Capillary-based separation instruments — CE-SDS purity assays, imaged capillary isoelectric focusing (icIEF) for charge-variant analysis, CE-mass spectrometry, and microfluidic chip electrophoresis for nucleic-acid fragment sizing — that replace slab-gel electrophoresis with automated, higher-resolution biopharma characterization and QC.

A patient's own T cells are collected, engineered with a chimeric antigen receptor (CAR) using a lentiviral vector, expanded and re-infused to kill cancer — an approved one-time living-drug class spanning CD19 lymphoma/leukemia and BCMA multiple myeloma, now advancing toward off-the-shelf allogeneic products.

Bench-top instruments that automate cell counting and viability assessment — image-based dye-exclusion counters, fluorescence-based analyzers and closed-cassette systems — replacing manual hemocytometer counting for daily cell-culture QC, bioreactor process monitoring and cell-therapy/cell-line release testing.

Chemically defined, serum-free and GMP-manufactured liquid and dry-powder cell culture media sold as a B2B consumable to biopharma, cell-therapy and vaccine manufacturers — the growth-supporting formulation itself, distinct from the equipment lines that manufacture it.

Cell-free protein synthesis (CFPS) bypasses the living cell: ribosomes and translation factors in a reaction tube deliver the target protein in hours, not weeks, with toxic and non-canonical amino acids incorporated.

Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical sequences — anchored by Codexis's CodeEvolver platform (the Merck sitagliptin transaminase case) in the US, Almac's biocatalysis CDMO in the UK, Lonza's HPAPI/biocatalysis toolkit in Switzerland, and Asymchem and WuXi AppTec's biocatalysis-enabled CDMO platforms in China.

A thin category by dedicated-system confirmation standards — clean-in-place/sterilize-in-place hardware for bioprocessing equipment sanitization — where three EU vendors have real, on-topic evidence, distinct from the enzymatic bio-CIP detergent chemistry already covered on this site.

Continuous particle counters, microbial air samplers and networked monitoring software that replace manual clipboard-and-spreadsheet particle logs with real-time, audit-trailed cleanroom classification data — the evidence base auditors and regulators use to confirm a GMP cleanroom actually holds its certified air-cleanliness grade between formal requalifications.

HVAC systems, HEPA/ULPA filtration and fan filter units (FFUs) that maintain the particle counts, air-change rates and pressure cascades required for ISO 14644-classified cleanrooms in pharmaceutical and cell/gene-therapy manufacturing, sold by dedicated filtration and airflow-control equipment makers.

Specialist insurance brokers who structure and place subject-injury, professional-indemnity and product-liability coverage for a clinical trial program, harmonizing the statutorily-required local insurance of every country a trial runs in into a single manageable placement.

Multi-tenant, remotely operated wet labs that execute user-submitted protocols via API and return structured data — the layer that turns biology into programmable infrastructure, decoupling experiment design from bench work and feeding the closed-loop AI-driven autonomous lab.

Specialized strategic advisory services guiding biopharma through the complex Chemistry, Manufacturing, and Controls (CMC) requirements to successfully file Biologics License Applications (BLA) and Marketing Authorisation Applications (MAA).

Collaborative robots (cobots) that work alongside human operators without safety caging — force-torque-limited arms deployed in cell-therapy manufacturing, sterile fill-finish and lab automation, delivering measured cost and throughput gains over both manual operation and fully caged industrial robotics.

Specialized courier and logistics networks that manage the temperature-controlled, chain-of-identity transport of autologous and allogeneic cell and gene therapy products between collection, manufacturing and patient-administration sites, sold by dedicated advanced-therapy-logistics providers rather than the cryogenic hardware itself.

Robotic platforms that image a microbial plate, score colonies by size, morphology and fluorescence, then pick and re-array 200–3,000 colonies an hour into fresh growth plates — the automated front end of strain engineering, directed evolution, CRISPR clone screening and microbiome culturomics.

Tissue-based immunohistochemistry (IHC) and FISH platforms that determine whether a specific patient is eligible for a specific targeted therapy, sold and regulated as a companion diagnostic (CDx) tied directly to a drug label — distinct from blood-based liquid-biopsy CDx: Ventana/Roche Tissue Diagnostics, Agilent Dako and Myriad Genetics in the US, 3D Medicines in China, and MedGenome in India.

Dry-electrode EEG wearables — headbands, earbuds and sleep masks — that read brainwave activity without gel or clinical setup, using on-device AI artifact removal and neurofeedback training to support meditation, focus and sleep, regulated as general wellness devices rather than medical BCI.

Pharma-sponsored accelerators and shared wet-lab hubs — JLABS, Bayer Co.Lab/G4A, Boehringer Ingelheim's BI X programs — that give startups equity-free or seed-funded access to lab infrastructure and IND-track mentorship in exchange for first-look licensing or M&A rights.

Outsourced, regulator-aligned training services that build and maintain GMP, GLP and GCP competency across biopharma workforces, producing inspection-ready training records under 21 CFR Part 11, EU GMP and ICH guidelines.

Cas-enzyme nucleic-acid detection — point-of-care molecular diagnostics from sample to lateral-flow readout.

Contract functional-genetic CRISPR screening (pooled sgRNA libraries, lentiviral delivery, NGS) — identifies cancer-resistance genes and drug targets in weeks.

Regulation Crowdfunding platforms and decentralized-science (DeSci) DAOs that let non-accredited retail investors fund early-stage biotech directly — via equity stakes or tokenized IP-NFTs — for projects too early-stage for traditional venture capital.

Liquid-nitrogen storage tanks, controlled-rate freezers and cryogenic shipping systems that preserve cell/gene therapies, biospecimens and other biological materials at ultra-low temperature across manufacturing, storage and distribution, sold by dedicated cryogenic equipment and logistics providers.

The stirred, draft-tube-baffled, melt and continuous crystallizers — plus the inline FBRM/PVM probes that close the loop on them — that turn a purified API molecule into a defined polymorph with a target particle-size distribution, the unit operation on which bioavailability, purity and downstream filterability all depend.

Advanced analytical devices detecting biological markers to enable rapid, precise disease identification and monitoring.

Software-as-medical-device treatments that deliver a regulator-cleared clinical intervention rather than general wellness support — prescription digital therapeutics for ADHD, insomnia, anxiety and depression, musculoskeletal digital rehabilitation and pediatric autism intervention: Akili Interactive, Big Health and Click Therapeutics in the US, Kaia Health in Germany, and ALSOLIFE in China.

High-speed centrifugal separators that stack conical discs to multiply settling area, clarifying fermentation broth and cell culture at 5,000–15,000 ×g with continuous automatic solids discharge — the primary harvest and clarification machine of bioprocessing, now extending into gamma-irradiated single-use bowls for small-batch and perfusion work.

Third-party audit firms that inspect pharmaceutical, biologic and cosmetic distributors and wholesalers against Good Distribution Practice (GDP) and supplier-qualification standards, giving a manufacturer independent assurance that its downstream supply-chain partners handle products to specification.

Folding single-stranded DNA into precision-programmed 3D nanostructures — drug-delivery nanorobots, vaccine scaffolds and metrology nanorulers.

The commercial gene-synthesis service and biofoundry layer of synthetic biology — turning digital DNA designs into delivered genes, clones and strain builds through phosphoramidite and emerging enzymatic synthesis, governed by pathogen-sequence biosecurity screening.

Skincare formulated against a genetic or epigenetic read of the buyer's skin — a cheek swab typed for ageing-related variants, then matched to actives — sold either as a direct-to-consumer product line or as a white-label engine other beauty brands license.

Downstream purification converts crude bioreactor harvests into clinical-grade drug substance — chromatography (Protein A, IEX, HIC), tangential-flow filtration, and viral clearance together account for >50% of biomanufacturing CAPEX. The global DSP market exceeds $5B and grows at >8% CAGR driven by mAb and cell-gene therapy demand.

The end-to-end R&D pipeline that carries a drug or vaccine candidate from target identification through Phase I-IV clinical trials to regulatory approval — a 7-15-year, billion-dollar process now being reshaped by personalized mRNA platforms, GLP-1 blockbuster economics and competing FDA, EMA and NMPA regulatory-acceleration reforms.

Direct-to-consumer genetic testing from saliva via SNP genotyping arrays and 30x whole-genome sequencing, with bioinformatic polygenic risk scoring and telemedicine gating of pathogenic findings (BRCA1/2), under FDA 510(k), EU IVDR and China's genetic-data sovereignty rules.

Deliberately engineering whole wild populations — from CRISPR gene drives that force 100% inheritance of a trait through a mosquito population in 6-20 generations to Wolbachia-infected and radiation-sterilized releases that collapse it instead — as a genetic complement to nature-based ecological engineering like constructed wetlands and living shorelines, all governed by an irreversibility problem no field release can undo.

Cartridge-based readers, kinetic microplate assays and reagent systems that detect bacterial endotoxin in injectable drugs, biologics and medical devices — the mandatory release test standing between every parenteral batch and market, now mid-transition from horseshoe-crab-derived LAL reagent to animal-free recombinant cascade reagents.

Cell-free directed synthesis of high-molecular-weight polymers utilizing purified recombinant enzymes ex vivo, eliminating metabolic constraints to produce ultra-pure biomaterials for regenerative medicine and high-end cosmetics.

Engineered enzymes and enzyme-target inhibitors are moving toward pharmaceutical protection from gluten exposure in celiac disease — a Barcelona-designed gastric enzyme validated in mouse models, a transglutaminase-2 inhibitor showing histologic protection in human trials, and a $35M Takeda-funded oral enzyme program whose later trial stage reportedly worsened mucosal damage.

Reading DNA-methylation patterns across hundreds of thousands of CpG sites to compute a person's biological age and pace of aging, rather than the calendar age on a birth certificate, turning a $229-799 saliva or blood test into the primary read-out for the longevity industry.

Turning genes on or off by rewriting DNA methylation and histone marks with dCas9 fusion proteins or zinc fingers — no DNA sequence change, but an effect that can be inherited across cell divisions.

Non-invasive breath-analyte devices aiming to monitor diabetes-relevant metabolic state without a fingerstick or implanted sensor — most commercially advanced platforms detect breath acetone/ketones as a metabolic proxy, while newer entrants target a more direct blood-glucose alert claim: PranaQ, Invoy Technologies, LEVL and PREEVNT, all US-based.

Cell-derived nanoscale vesicles (30-150 nm) used as native regenerative-medicine agents or engineered as biocompatible drug-delivery vehicles for RNA, protein and gene-editing cargo, crossing biological barriers artificial lipid nanoparticles cannot.

Specialized biologic, diagnostic and live-biotherapeutic products for conditions that affect exclusively or disproportionately women — non-invasive endometriosis testing, ovarian-longevity therapeutics, vaginal-microbiome LBPs and cfDNA prenatal screening, under FDA, EU IVDR/EMA and NMPA oversight.

Matching platforms and contract manufacturers that connect biotech companies needing fermentation capacity with idle or available bioreactor capacity, easing the scale-up bottleneck between lab-scale precision fermentation and commercial-volume production.

High-precision sterile filling of advanced biological drugs into final delivery formats using isolated robotic environments.

Bench-top and process-scale instruments that measure and sort individual cells by fluorescence and light scatter — spectral analyzers, high-speed sorters and acoustic-focusing cytometers — the standard tool for CAR-T/cell-therapy release, immunophenotyping and cell-line development across bioproduction.

Overhead gantry and robotic-arm hardware that physically transports microplates and labware between instruments in an automated wet-lab workflow — the plate-movement layer distinct from the liquid-handling and colony-picking instruments it feeds — sold by four specialists (HighRes Biosolutions, Thermo Fisher, Peak Analysis and Automation, Agilent) spanning integrated automation-system builders through single-instrument microplate movers.

Creating completely novel, non-natural protein structures and sequences from scratch using diffusion networks and large language models for therapeutics and biosensors.

Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.

Sequencing-based services that track pathogen genomic evolution and spread for public health response — traveler/airport biosurveillance, portable field sequencing and national metagenomic surveillance programs — the genomic-analysis service layer, not the sample-collection infrastructure: Ginkgo Bioworks (Concentric) in the US, Oxford Nanopore Technologies and the Wellcome Sanger Institute/UKHSA in the UK, BGI Genomics in China, and the Rajiv Gandhi Centre for Biotechnology in India.

Writing genomes rather than just reading them — DNA synthesis at scale, de novo synthetic chromosomes and DNA-based digital data storage, complementing the sequencing/analysis side of genomics.

Selectively clearing senescent 'zombie' cells or suppressing their inflammatory secretome to treat age-related disease at its molecular root, rather than one downstream condition at a time.

Dedicated repository platforms that version, route for approval and retain controlled GMP documents — SOPs, batch records, validation protocols — as their own connected content layer, distinct from the deviation/CAPA/training hub a broader eQMS runs on top of the same documents.

Disposable and reusable cleanroom garments, gloves, wipes and gowning-room procedures that control personnel-shed particle and microbial contamination in ISO-14644-classified pharmaceutical cleanrooms, sold by dedicated apparel and consumables manufacturers.

Regulated door-to-door transport of Category A and B infectious substances under IATA Packing Instructions 602/650, using triple packaging, biosafety couriers and chain-of-custody tracking.

Bioreactor hardware engineered to sustain far higher viable-cell densities than a conventional stirred tank — Repligen's XCell ATF perfusion system (100M+ cells/mL), PBS Biotech's Vertical-Wheel bioreactors, Univercells Technologies' scale-X fixed-bed platform, and Cellexus's CellMaker airlift bioreactors — the equipment layer that lets a fed-batch or perfusion process pack more cells and more product into the same reactor volume.

Self-administered blood collection for consumer health testing, either mailed to a certified laboratory or drawn at a retail microsample station, returning results outside a clinic visit — distinct from clinic point-of-care testing: LetsGetChecked and Everlywell (mail-in kits) and Babson Diagnostics (retail microsample testing) in the US, and Thriva in the UK.

Bench-top liquid chromatography systems — HPLC and ultra-high-performance UPLC platforms — that separate and quantify proteins, peptides, small molecules and impurities ahead of UV, fluorescence or mass-spectrometry detection, the workhorse instrument for biopharma purity testing, release assays and formulation characterization.

Health-economic evidence packages — systematic clinical-evidence reviews, cost-effectiveness and budget-impact modeling, patient-perspective data — that a biopharma manufacturer must assemble to win pricing and reimbursement approval from a national HTA body (NICE, G-BA, CADTH), prepared by specialty consultancies against strict statutory deadlines (56 days for a NICE Single Technology Appraisal), increasingly using AI to compress a traditionally months-long process.

Surgically or subcutaneously implanted sensors that continuously monitor a chronic-disease parameter for months to years without an external wearable — implantable continuous glucose monitors and insertable cardiac monitors — distinct from external wearables and ingested/swallowed sensors: Senseonics' Eversense 365 in the US, Medtronic's LINQ II and Boston Scientific's LUX-Dx cardiac monitors in the US, Biotronik's BIOMONITOR in Germany, and MicroPort in China.

Deriving functional human eggs and sperm entirely outside the body from reprogrammed stem cells, aimed at reversing absolute infertility and enabling genome-corrected embryos.

One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.

Swallowed capsule devices that image the GI tract or confirm medication ingestion as they transit the body, requiring no sedation or implantation — distinct from surgically implanted sensors: Medtronic's PillCam and CapsoVision's CapsoCam capsule endoscopy in the US, etectRx's ID-Cap ingestible event marker in the US, and Ankon Technologies' magnetically controlled capsule endoscopy in China.

Real-time, in-the-operating-room molecular and optical tissue identification — fluorescence imaging agents, OCT, stimulated Raman histology and mass-spectrometry tissue analysis — that lets surgeons assess tumor margins during the procedure instead of waiting on frozen-section pathology: On Target Laboratories and Dilon Technologies (fluorescence/RF-spectroscopy margin agents), Perimeter Medical Imaging AI (AI-enabled OCT), Invenio Imaging (stimulated Raman histology) in the US, and photonamic and Imperial College London (iKnife/REIMS) in Europe.

High-throughput robotic liquid handling systems and integrated laboratory automation platforms that exponentially increase assay throughput, eliminate human error, and enable next-generation genomics and synthetic biology.

High-throughput robotic systems and liquid handling workstations driving autonomous, reproducible bio-research and screening.

Software that tracks what equipment and consumables a life-science lab owns, who is using them and when, and routes the reorder through a multi-supplier marketplace — turning a spreadsheet-and-email purchasing habit into a scheduled, auditable source-to-pay record.

Software that guides a lab analyst step by step through a validated test method — enforcing sequence, capturing instrument data automatically and generating an audit-trailed electronic record — replacing the paper worksheet as the way regulated QC and R&D labs prove a test was actually run as written.

Integrated Laboratory Information Management Systems (LIMS) and Electronic Lab Notebooks (ELN) serving as the digital backbone for biopharma R&D, cell line development, and cGMP commercial manufacturing.

Blood-based detection and quantification of circulating tumor DNA (ctDNA) for cancer companion diagnostics and molecular residual disease (MRD) monitoring, replacing or supplementing tissue biopsy — led by Guardant Health, Natera and Foundation Medicine in the US, Sysmex Inostics in the EU, MedGenome in India, and Burning Rock Biotech in China.

Viability-preserving cold-chain last-mile delivery of live microbial biopreparations — phages, probiotics and biofertilizers — using PCM isothermal packaging, IoT loggers and PMA-qPCR viability audit at the point of application.

Contract development, technology-transfer and local-build services that establish in-country or regional biomanufacturing so a biologic or vaccine qualifies for market access, procurement preference and supply security in target jurisdictions.

Vacuum freeze-drying systems that sublime ice from filled vials to yield shelf-stable lyophilized biologics, vaccines and injectables, engineered around controlled ice nucleation, natural refrigerants and PAT/RTRT cycle control under EU GMP Annex 1 and ICH Q13.

High-resolution and tandem mass spectrometers — Orbitrap, time-of-flight and triple-quadrupole platforms — that characterize protein identity, post-translational modifications, impurities and peptide biomarkers, from deep proteomics research through GxP biopharma release and clinical/forensic quantitation.

GMP equipment lines for B2B dry-powder and liquid cell-culture media — cryogenic pin milling, ribbon-blend homogenisation and 0.1 um sterile fill — supplying the chemically-defined, animal-component-free media demand of mAb and cell-therapy biomanufacturing.

A thin category by dedicated-product confirmation standards — cell-culture media powder dissolution, mixing, and delivery hardware — where three major bioprocess-equipment vendors have real, on-topic 2026 evidence, but each is confirmed at the product-line rather than dedicated-standalone-business level.

Surface-engineering and coating technologies that govern how a catheter, guidewire, stent or implant actually meets living tissue — hydrophilic lubricious coatings, bioactive anticoagulant polymer layers, and drug-eluting coating systems — spanning Formacoat, Biocoat and Integer Holdings in the US, Freudenberg Medical and DSM Biomedical in Europe, and Sino Medical Sciences Technology in China.

Contract research platforms that profile the small-molecule metabolome of blood, tissue or bioreactor broth via LC-MS/GC-MS, turning raw chromatography data into biomarker panels, drug-response readouts and bioprocess metabolic profiles for pharma, nutrition and industrial-fermentation clients.

Stool- or swab-based sequencing panels that profile the gut or GI microbiome for consumer wellness insight or clinical pathogen/dysbiosis detection, distinct from general human genomics services: Viome (US, consumer wellness) and Codex Genetics (US, clinical metagenomics), Sequentia Biotech's IVDR-CE-marked MICK Clinical in Spain, Realbio Genomics in China, and Yaazh Xenomics in India.

Live biotherapeutic products (LBPs) — standardized, GMP-manufactured microbial consortia approved as drugs for recurrent C. difficile, inflammatory bowel disease and immuno-oncology support.

Small (100–300 μm) suspended particles whose surface lets anchorage-dependent cells grow inside ordinary stirred-tank and single-use bioreactors — the consumable that turns adherent biology (vaccines, cell therapy, cultivated meat) into a scalable, GMP industrial process.

Laboratory and production-scale machinery — spray drying towers, laminar-jet encapsulators and drip-casting microsphere systems — that encapsulates active ingredients, probiotics, cells or flavors in a protective wall material, sold as capital equipment to pharmaceutical, food and biotech manufacturers by specialty equipment builders (Solutions Vobis, BRACE, Buchi, Changzhou Yongchang) rather than the finished encapsulated ingredient itself.

Automated mini- and micro-bioreactors (1-250 mL) running 24-48 cultures in parallel that map a bioprocess Design Space in days rather than months — the high-throughput on-ramp to cell-line, strain and upstream-process development, led by the German ambr, BioLector and DASbox platforms.

Prefabricated, autonomous cleanroom infrastructures delivering rapid deployment, scalable capacity, and guaranteed cGMP compliance for the rapidly evolving biomanufacturing and cell therapy sectors.

The mixers, skids and continuous-flow reactors that bring an mRNA payload and a four-lipid ethanol blend together in microseconds to self-assemble 80–120 nm lipid nanoparticles — the hardware layer behind every commercial mRNA vaccine and the in-vivo delivery system for the next generation of gene therapy.

Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression.

A single blood draw screening asymptomatic, average-risk individuals for signals of dozens of cancer types simultaneously, aiming to catch cancer before symptoms appear — distinct from treatment-matched companion diagnostics: GRAIL's Galleri (US), Exact Sciences' Cancerguard (US) and Freenome (US), Novigenix in Switzerland, and Singlera Genomics in China.

Regulatory-affairs consultancies and eCTD submission software that manage biopharmaceutical filings across the FDA, EMA, China's NMPA and Japan's PMDA simultaneously — helping a biologics or biotech developer sequence and harmonize approvals across the world's major drug-regulatory jurisdictions.

Integrative genomic, transcriptomic and proteomic oncology profiling platforms that combine multiple molecular data layers into a single treatment-matching report, broader than a single drug-label companion diagnostic: Tempus AI and Caris Life Sciences in the US, Sophia Genetics in Switzerland, Geneseeq Technology in China, and 1cell.ai in India.

Regulated pre-approval access to investigational biopharmaceuticals for patients with serious or life-threatening disease and no satisfactory alternative — operated as a managed-access service spanning eligibility, regulatory submission, GMP drug sourcing and pharmacovigilance.

Brain–computer interfaces that read motor and speech cortex activity and decode intent into text, synthesized voice or robotic movement — spanning invasive intracortical arrays, endovascular stent-electrodes, semi-invasive ECoG and non-invasive EEG, under FDA IDE trials, EU MDR and NMPA oversight.

CAR-NK and NK-cell therapy — allogeneic, off-the-shelf effector cells with low toxicity (minimal CRS, no GVHD) against solid and haematological cancers; iPSC-NK is the scalable platform.

Short synthetic oligonucleotides — siRNA and antisense — bind a target messenger RNA to silence or reprogram a disease gene, enabled by GalNAc liver targeting and sugar/backbone chemistries, with multiple approved drugs across rare, neurological and cardiometabolic disease.

Additive manufacturing of living cells and biomaterials to construct functional tissue models and transplantable organs.

Microphysiological systems mimicking human organs in vitro to replace animal testing and accelerate personalized medicine.

Transient expression of Yamanaka reprogramming factors to reverse epigenetic markers of cellular aging without erasing cell identity — OSK gene therapy, AI-discovered reprogramming payloads and safer single-gene rejuvenation targets: Altos Labs, Retro Biosciences, NewLimit and Life Biosciences in the US, Shift Bioscience in the UK, and JingTong Life in China.

Bench-top instruments that size and charge-characterize particles from nanometers to millimeters — dynamic light scattering, laser diffraction, nanoparticle tracking and multi-angle light scattering — the standard release and formulation-R&D toolkit for lipid nanoparticles, biologics aggregates, extracellular vesicles and industrial powders.

HEPA-filtered pass boxes and interlocked airlock chambers that move materials between cleanroom classification zones without breaking containment — static and dynamic (actively purified/decontaminated) formats sold by five specialist manufacturers spanning the US, Germany and China (Franz Ziel, Terra Universal, Clean Rooms International, Airkey Envirotech, Suzhou Hansen Cleanroom Technology).

Computational patient models and virtual trial simulations used to reduce, accelerate or de-risk clinical development — AI-generated synthetic control arms, physiologically-based pharmacokinetic modeling, preclinical-to-clinical translation AI and causal-AI virtual patient simulation: Unlearn.AI, Certara and VeriSIM Life in the US, and Novadiscovery (Nova In Silico) in France.

Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.

Molecular diagnostics leveraging NGS, liquid biopsy, and AI for precision medicine and targeted therapies.

Advanced bioremediation targeting per- and polyfluoroalkyl substances (PFAS) using engineered proteins, specialized microbial consortia, and bio-based adsorbents to break down forever chemicals.

pH electrodes and dissolved-oxygen (DO) sensors that provide the fundamental process-control measurements inside a bioreactor — reusable and single-use, polarographic and optical formats — the base-layer sensor hardware beneath the broader PAT analytics stack (spectroscopic, chromatographic and mass-spectrometry instrumentation).

Multimode microplate readers that measure absorbance, fluorescence, luminescence and time-resolved FRET across 96-, 384- and 1536-well plates — the shared detection backbone behind ELISA, cell viability, reporter-gene and high-throughput screening assays across biopharma R&D and QC.

Lab-free, sample-to-answer molecular testing platforms delivering PCR-grade results at the bedside, clinic or field site in minutes rather than the hours a central lab requires: Cepheid's GeneXpert (Danaher) and bioMérieux's BIOFIRE cartridge-based systems, Abbott's ID NOW isothermal platform, Sansure Biotech's domestic POCT scale-up in China, and Molbio Diagnostics' Truenat chip-based platform serving resource-limited settings from India.

Search-and-replace genome editing with a Cas9 nickase fused to a reverse transcriptase and an extended pegRNA — writing all 12 base substitutions and small indels without a double-strand break.

CRO-delivered three-stage process validation and IQ/OQ/PQ qualification of biopharma equipment — media fills, cleaning validation, CSV and viral clearance under FDA/EudraLex Annex 1 cGMP.

Bifunctional small molecules that recruit an E3 ubiquitin ligase to a disease protein, tagging it for proteasomal destruction — an event-driven, catalytic drug modality approaching its first approval with Arvinas's estrogen-receptor degrader vepdegestrant, and a deep pipeline across IRAK4, IKZF and BTK targets.

Mass-spectrometry proteomics as a contract research service — deep DIA proteome profiling, targeted MRM/PRM and affinity proteomics for biomarker discovery and pharmacoproteomics.

Psychoactive-compound therapies (psilocybin, MDMA, 5-MeO-DMT) and next-generation non-hallucinogenic psychoplastogens that trigger rapid synaptogenesis via serotonin 5-HT2A receptor signaling, targeting treatment-resistant depression and PTSD — a field with genuine 2026 clinical wins and a high-profile FDA regulatory setback.

Electronic quality management systems (eQMS) that digitize document control, deviation/CAPA, training records and audit management for biologics and biopharma manufacturers into one 21 CFR Part 11-compliant record, with an AI-assisted compliance layer now reshaping how fast that record can be built and audited.

Radioactive compounds that pair a tumor-targeting vector with a diagnostic or therapeutic isotope — 'see what you treat, treat what you see' — now commercial at multi-hundred-million-dollar manufacturing scale.

Platforms that determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours instead of the 2-3 days conventional culture-based susceptibility testing requires, guiding targeted rather than empiric antibiotic therapy: Accelerate Diagnostics and T2 Biosystems and Selux Diagnostics in the US, Q-linea in Sweden, and Autobio Diagnostics in China.

Recombinant and next-generation engineered botulinum neurotoxins (BoNT) — expressed via DNA technology or reformulated as complex-free / ready-to-use liquids — are displacing traditional Clostridium botulinum fermentation: AbbVie/Allergan's Boey® (trenibotulinumtoxinE, recombinant serotype E) won EU and Health Canada approval in 2026 with onset as early as 8 hours and a 2-3 week duration across 2,100+ Phase 3 patients; Galderma's Relfydess™ (relabotulinumtoxinA, PEARL™ Technology ready-to-use liquid) reached 33 markets including EU approval across 16 countries in 2026; Merz's Xeomin (incobotulinumtoxinA, complexing-protein-free naked toxin) holds 79-country approval; Eirion's AI-09 ready-to-use recombinant liquid injectable achieved 6-month duration at the highest dose in a 96-subject Phase 1-2 trial. China's Lanzhou/CNBG Hengli® (衡力) — the country's first domestic BoNT-A (2002 approval, 30+ years lineage) — leads the local market with first-in-China 2025-2026 approvals for axillary hyperhidrosis and benign masseter hypertrophy while domestic recombinant R&D remains pre-commercial.

Precision-fermentation-derived collagen and gelatin — produced in engineered yeast or via plant molecular farming rather than animal hide and bone extraction — for food, dietary-supplement, wound-care and tissue-engineering applications, eliminating prion-contamination risk and batch variability.

Precision-fermentation collagen engineered specifically for skincare and injectable aesthetic medicine — matching the human collagen sequence, free of prion and allergenicity risk, and small enough to penetrate skin's epidermal barrier — powering China's dominant recombinant-collagen skincare industry and premium Western dermal-filler and cosmetic-ingredient lines.

Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor blood supply and viral contamination risk since the 1940s — with biosynthetic production in yeast (Pichia pastoris, Hansenula polymorpha) or plant (rice endosperm) hosts: Healthgen Biotech's OsrHSA (奥福民®) became the world's first NMPA-approved rHSA injection (July 2025) with 1-million-vial annual capacity and a 22-centre Phase III in decompensated liver cirrhosis; InVitria's Exbumin (rice-derived, ExpressTec platform) is the excipient in Merck's ERVEBO Ebola vaccine — the first FDA/EMA/PMDA-approved rice rHSA in an injectable — and Optibumin 25 (launched April 2025) is the first recombinant 25% HSA for closed-system biomanufacturing; Proliant launched AlbufreeDX (June 24, 2026) for diagnostics; Basic Pharma (NL) + ARTES Biotechnology (DE) make Hansenula polymorpha rHSA; Shilpa Medicare's sRbumin® became India's first rHA Phase 1 completion (August 2024), with CDSCO Phase III nod (November 2024) and an Orion Europe commercialization deal. The global rHSA market stood at USD 166M in 2025, projected to USD 421M by 2035 (CAGR 9.75%).

Authenticated microbial type strains and WHO biological reference materials — the calibrated living standards underpinning pharmaceutical QC, diagnostics, taxonomy and patent deposit, held by a global network of biological resource centers from the century-old ATCC to NIBSC.

Software platforms that continuously monitor global drug and biologics regulatory changes — guidance updates, Candidate List additions, post-approval variation triggers — and use AI to filter and prioritize which changes affect a specific biopharmaceutical product portfolio.

Eye-scan technologies that detect Alzheimer's and other neurodegenerative-disease biomarkers directly in the retina — a window onto brain pathology accessible without imaging the brain itself — spanning hyperspectral imaging, OCT-based structural biomarkers and retinal amyloid detection: RetiSpec and NeuroVision Imaging in North America, Optina Diagnostics in Canada, and Heidelberg Engineering in Germany.

Engineered oligonucleotides that recruit the cell's endogenous ADAR enzymes to rewrite a pathogenic adenosine to inosine on disease transcripts — a reversible, titratable alternative to DNA editing now in clinical validation, with Wave's WVE-006 (AATD, RestorAATion-2) the lead asset and ProQR's Axiomer platform delivering the first clinical proof of mechanism.

Automated ultra-low-temperature and liquid-nitrogen storage systems that robotically retrieve, track and manage individual sample tubes or plates at scale — the equipment layer behind population biobanks, clinical-trial biorepositories and biopharma sample archives, replacing manual freezer racks with barcode-tracked, walk-away retrieval.

Industrial automation software orchestrating complex bioreactor operations and enforcing regulatory compliance through electronic batch records.

Public-private manufacturing-innovation institutes that operate shared pilot- and demonstration-scale biomanufacturing facilities, letting a biologic developer run small-batch production and prove out a process before committing capital to a dedicated commercial-scale plant.

A genuinely thin, single-vendor automation category — fully automated, unattended seed-train expansion for adherent cell culture — distinct from the broader wave/single-use bioreactor hardware market already covered on this site.

The vision inspection, 2D-Data-Matrix printing, aggregation and multi-enterprise network software that stamp a unique identity onto every saleable drug unit and follow it from factory to dispenser — the equipment layer that makes pharma supply chains DSCSA-, FMD- and China-code-compliant, anti-counterfeit and recall-ready.

Recombinant silk fibroin and spider-silk proteins — expressed via microbial precision fermentation (Spiber Brewed Protein™, AMSilk Biosteel, Bolt Threads MicroSilk), transgenic *Bombyx mori* silkworms (Kraig Biocraft MaSp1/MaSp2), or purified from *Bombyx mori* cocoons for biomaterials (Sofregen Medical SilkVoice FDA-cleared ENT device) — have crossed into commercial scale in 2026: Spiber's Rayong Thailand plant and 2025 Italian-mill partnerships (Botto Giuseppe, Manifattura Sesia, Achille Pinto) produced 100% Brewed Protein yarns at industrial tonnage; AMSilk's bioengineered yarns debuted in Balenciaga Spring 2026 collection and Ajinomoto Foods Europe's dedicated 160 m³ Nesle France fermentation plant came online July 2026; Kraig Biocraft hit 1.3 metric tons of recombinant spider silk cocoons in March 2026 (1.8 MT in April) via transgenic silkworms in Vietnam; Sofregen Medical's SilkVoice holds two FDA 510(k) clearances (K180631, K240919) for vocal cord medialization, validated in a 33-patient Laryngoscope 2026 study. Bolt Threads patented recombinant silk polypeptide as a silicone replacement in personal care (US20260069524A1, March 2026).

Per-cell mapping of genomes, transcriptomes and proteomes as a contracted service — moving biology from bulk-average reads to cell-by-cell atlases for drug-target discovery and patient stratification.

Pre-sterilized, fully integrated polymer fluid paths and containment bags that eliminate cross-contamination, bypass intensive cleaning validation, and drastically compress biomanufacturing facility footprints.

Gamma-irradiated single-use bag bioreactors in the 50-2000 L stirred-tank class — Sartorius Biostat STR, Cytiva Xcellerex XDR, Thermo Fisher HyPerforma, Merck Mobius — that replaced stainless steel for clinical and commercial mAb, vaccine and cell-and-gene-therapy manufacturing, cutting facility build-out from years to weeks and underpinning the CDMO economy.

Disposable bioreactors, bags and tubing plus modular factories (KUBio — 12–18 months vs 5–7 years) cut capex and cross-contamination, making biomanufacturing flexible and multi-product.

Mapping chromatin accessibility, DNA methylation and histone marks directly on a tissue section instead of a dissociated cell suspension, using in situ Tn5 transposition and microfluidic barcoding to build 3D atlases of a tumor's epigenetic state at 10-micron resolution — the layer of hardware and reagents beneath precision oncology's biggest 2026 push.

Mapping gene expression — and increasingly proteins — directly onto intact tissue sections, so each transcript keeps its x/y address and the tumour microenvironment becomes a navigable map rather than a bulk average.

Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast's Ryoncil for steroid-refractory GVHD and TiGenix's Alofisel for Crohn's fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia.

Membrane-filtration pump systems, automated colony-detection platforms and rapid microbial detection instruments that confirm a parenteral product is free of viable microorganisms before release — a mandatory 14-day compendial test now increasingly compressed to hours or days by validated rapid alternative methods.

0.2-micron-rated membrane filters, cartridges and syringe filters that remove bioburden from process fluids, buffers and final drug product before fill-finish — a distinct hardware/consumables category from resin-based chromatography, sold by four specialist manufacturers (Sartorius, Cobetter, Meissner Filtration Products, Parker Bioscience Filtration) spanning syringe-scale lab filters through single-use process-scale assemblies.

Cryo-electron microscopy as a contract research service — atomic 3D structures of membrane proteins and drug targets for structure-based drug design, displacing X-ray crystallography.

The engineering of biology — designing DNA, cells and genetic circuits on computers, building them in biofoundries and scaling them into chemicals, materials and ingredients through the Design-Build-Test-Learn cycle.

Engineered, exogenous reporter molecules — activity-based nanosensors, synthetic gene circuits and volatile-organic-compound probes — administered to a patient to generate an amplified, easily measured disease signal that no endogenous biomarker naturally produces: Glympse Bio, Earli and ZymoSense in the US, and Owlstone Medical's EVOC breath-probe platform in the UK.

Patient T cells are engineered with a high-affinity T-cell receptor (TCR) that recognises a peptide-MHC complex inside a solid-tumour cell — an approved one-time therapy reaching tumour targets CAR-T cannot, led by Adaptimmune's Tecelra and Immunocore's Kimmtrak, with a deeper pipeline advancing MAGE-A4, NY-ESO-1, gp100 and PRAME targets.

Point-of-care diagnostic testing of a microliter tear sample for dry eye, ocular allergy and inflammatory biomarkers, avoiding blood draw or invasive sampling: Trukera Medical's tear osmolarity system and Lacrisciences' tear IgE allergy test and QuidelOrtho's InflammaDry inflammatory marker test in the US, and DiagnosTear's TearX platform in France.

Advanced process simulation and financial modeling services that determine the commercial viability, optimal facility sizing, and Cost of Goods Sold (COGS) for emerging biomanufacturing technologies before capital is deployed.

TIL therapy — autologous tumor-infiltrating T-cells with polyclonal specificity; the first approved drug Lifileucel (Amtagvi, Iovance, FDA 2024) is a breakthrough in metastatic melanoma.

Contract safety assessment that takes a drug candidate from in-silico ADMET triage through in-vitro panels (hepatotoxicity, hERG, CYP induction) to GLP in-vivo studies, delivering the IND-enabling toxicity package regulators require — now augmented by toxicogenomics and virtual control groups.

Specialized venture studios, wet-lab accelerators and academic nonprofit networks that convert university biotech IP into funded companies, closing the gap between a PhD discovery and a commercial spin-off.

Advanced veterinary biotechnology focusing on mRNA vaccines, recombinant proteins, and novel biologics to combat zoonotic and livestock diseases with rapid-response platforms.

Direct-to-consumer DNA testing of dogs and cats — a stack from cheek-swab collection to a LIMS-verified veterinary genetic passport screening hundreds of inherited disease risks.

Aggregate, non-invasive molecular surveillance of municipal sewage for pathogens, antimicrobial resistance and substance use — an early-warning public-health intelligence service built on viral concentration, droplet-digital PCR and metagenomic sequencing.

Purification trains for laboratory and process-area water — stills, reverse-osmosis and electrodeionization systems, Type I–III stations, storage and distribution loops — held to the 18.2 MΩ·cm ultrapure ceiling. The table carries three vendors with verified, on-topic dossiers and clean boundaries against sibling pages.

Single-use wave and rocking-bag bioreactors — Cytiva WAVE/Xuri, Sartorius Biostat RM, Thermo Fisher HyPerforma Rocker and Applitech AbioWave — that expand CHO, HEK293, stem-cell and cell-therapy seed trains under low-shear wave mixing without stirred impellers or clean-in-place.

Wearable biodiagnostics and continuous monitoring systems enabling real-time precision health management.

Transplanting organs from multiplex gene-edited pigs into humans to address the chronic shortage of donor organs, now moving from expanded-access compassionate cases into FDA-cleared clinical trials.